Infection, inflammation, and atherosclerosis

Stroke

Volumn 34, Issue 2, 2003, Pages 333-334

  Spence, J David ^a,c   Norris, John ^b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Helicobacter pylori; Infection; Inflammation

Indexed keywords

ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; INFECTION; INFLAMMATION; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; STROKE; SUPERINFECTION;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHLAMYDOPHILA INFECTIONS; HELICOBACTER INFECTIONS; HUMANS; INFECTION; INFLAMMATION; MANNOSE-BINDING LECTIN; RISK FACTORS;

EID: 0037322607     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000054049.65350.EA     Document Type: Short Survey

References (39)

1. Futterman LG, Lemberg L. Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. Am J Crit Care. 1998;7:240-244.
2. Gordon T, Garcia-Palmieri MR, Kagan A, Kannel WB, Schiffman J. Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chron Dis. 1974;27:329-344.
3. Spence JD, Barnett PA, Bulman DE, Hegele RA. An approach to ascertain probands with a non-traditional risk factor for carotid atherosclerosis. Atherosclerosis. 1999;144:429-434.
4. Marenberg ME, Risch N, Berkman LF, Floderus B. de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041-1046.
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565.
6. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998;148:937-948.
7. Fong IW. Infections and their role in atherosclerotic vascular disease. J Am Dent Assoc. 2002;133(suppl):7S-13S.
8. Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Northfield TC, Mendall MA. Fibrinogen: a link between chronic infection and coronary heart disease. Lancet. 1994;343:1634-1635.
9. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ. 2000;163:49-56.
10. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997;349: 1391-1392.
11. Gurfinkel E, Bozovich G. Chlamydia pneumoniae: inflammation and instability of the atherosclerotic plaque. Atherosclerosis. 1998;140(suppl 1):S31-S35.
12. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am Heart J. 1999;138(5 Pt 2):S534-S536.
13. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-636.
14. Campbell LA, Kuo CC, Grayston JT. Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis. 1998;4:571-579.
15. Saikku P. Chlamydia pneunioniae and atherosclerosis: an update. Scand J Infect Dis. 1997;104(suppl):53-56.
16. Shafran SD, Conly JM. Does Chlamydia pneumoniae cause coronary atherosclerosis and should we all take macrolides? Can J Cardiol 1997; 13:1017-1019.
17. Carlsson J, Miketic S, Mueller KH, Brom J, Ross R, von Essen R, Tebbe U. Previous cytomeglatovirus or Chlomydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty. Lancet. 1997;351:1225.
18. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 1997;96:2144-2148.
19. Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke. 1998;29:404-410.
20. Wimmer ML, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke. 1996;27: 2207-2210.
21. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Home BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000;102:1755-1760.
22. Gurfinkel E, Bozovich G, Beck E, Testa E. Livellara B, Mautner B. Treatment with the antibiotic mxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS Study. Eur Heart J. 1999;20:121-127.
23. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
24. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 1999;283:1335-1339.
25. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48-52.
26. Singh RK, McMahon AD, Patel H, Packard CJ, Rathbone BJ, Samani NJ. Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart. 2002; 88:43-46.
27. Farsak B, Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, Kes S, Tokgozoglu L. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol. 2000;38:4408-441.
28. Blasi F, Denti F, Erba M, Cosentini R, Raccaneili R, Rinaldi A. Fagetti L, Esposito G, Ruberti U, Allegra L. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol. 1996;34:2766-2769.
29. Danesh J, Koreth J, Youngman L, Collins R, Arnold JR, Balarajan Y, McGee J, Roskell D. Is Helicobacter pylori a factor in coronary atherosclerosis? J Clin Microbiol 1999;37:1651.
30. Ezekowitz RA. Genetic heterogeneity of mannose-binding proteins: the Jekyll and Hyde of innate immunity? Am J Hum Genet 1998;62:6-9.
31. Turner MW. Mannose-binding lectin (MBL) in health and disease. Immunobiology. 1998;199:327-339.
32. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease: Meningococcal Research Group. Lancet. 1999; 353:1049-1053.
33. Swanson AF, Ezekowitz RA, Lee A, Kuo CC. Human mannose-binding protein inhibits infection of HeLa cells by Chlamydia trachomatis. Infect Immun. 1998;66:1607-1612.
34. Madsen HO, Videm V, Svejgaard A, Svennevig JL, Garred P. Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet. 1998;352:959-960.
35. Hegele RA, Ban MR, Anderson CM, Spence JD. Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Investig Med. 2000;48:198-202.
36. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis. 2000;181(suppl 3):S402-S410.
37. Danesh J, Whincup P, Lewington S, Walker M, Lennon L, Thomson A, Wong YK, Zhou X, Ward M. Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23:371-375.
38. Hegele RA. The pathogenesis of atherosclerosis. Clin Chim Acta. 1996; 246:21-38.
39. Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke. 2002;33:862-875.